-+ 0.00%
-+ 0.00%
-+ 0.00%

Canaccord Genuity Maintains Buy on AngioDynamics, Lowers Price Target to $16

Benzinga·04/06/2026 15:09:58
Listen to the news
Canaccord Genuity analyst John Young maintains AngioDynamics (NASDAQ:ANGO) with a Buy and lowers the price target from $18 to $16.